Department of Internal Medicine I, Regensburg University Hospital, 93053 Regensburg, Germany.
Children's University Hospital (KUNO), Regensburg University Hospital, 93053 Regensburg, Germany.
Int J Mol Sci. 2019 Aug 12;20(16):3919. doi: 10.3390/ijms20163919.
The chemoattractant adipokine chemerin is related to the metabolic syndrome, which is a risk factor for different cancers. Recent studies provide evidence that chemerin is an important molecule in colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Serum chemerin is high in CRC patients and low in HCC patients and may serve as a differential diagnostic marker for HCC and liver metastases from CRC. To this end, serum chemerin was measured in 36 patients with CRC metastases, 32 patients with HCC and 49 non-tumor patients by ELISA. Chemerin serum protein levels were, however, similar in the three cohorts. Serum chemerin was higher in hypertensive than normotensive tumor patients but not controls. Cancer patients with hypercholesterolemia or hyperuricemia also had increased serum chemerin. When patients with these comorbidities were excluded from the calculation, chemerin was higher in CRC than HCC patients but did not differ from controls. Chemerin did not correlate with the tumor markers carcinoembryonic antigen, carbohydrate antigen 19-9 and alpha-fetoprotein in both cohorts and was not changed with tumor-node-metastasis stage in HCC. Chemerin was not associated with hepatic fat, liver inflammation and fibrosis. To conclude, systemic chemerin did not discriminate between CRC metastases and HCC. Comorbidities among tumor patients were linked with elevated systemic chemerin.
趋化因子脂肪因子 chemerin 与代谢综合征有关，而代谢综合征是多种癌症的危险因素。最近的研究表明 chemerin 是结直肠癌 (CRC) 和肝细胞癌 (HCC) 的重要分子。CRC 患者的血清 chemerin 水平较高，HCC 患者的血清 chemerin 水平较低，可能作为 HCC 和 CRC 肝转移的鉴别诊断标志物。为此，通过 ELISA 法检测了 36 例 CRC 转移患者、32 例 HCC 患者和 49 例非肿瘤患者的血清 chemerin。然而，三组患者的血清 chemerin 蛋白水平相似。与血压正常的肿瘤患者相比，高血压肿瘤患者的血清 chemerin 水平更高，但与对照组相比无差异。患有高胆固醇血症或高尿酸血症的癌症患者的血清 chemerin 水平也升高。当从计算中排除这些合并症患者时，CRC 患者的血清 chemerin 水平高于 HCC 患者，但与对照组无差异。在两组患者中，chemerin 与肿瘤标志物癌胚抗原、碳水化合物抗原 19-9 和甲胎蛋白均无相关性，且在 HCC 中与肿瘤-淋巴结-转移分期无关。chemerin 与肝脂肪、肝炎症和纤维化无关。总之，系统性 chemerin 不能区分 CRC 转移和 HCC。肿瘤患者的合并症与全身性 chemerin 升高有关。
